MolDX: Oncotype DX® Breast Cancer for DCIS (Genomic Health™)

This contractor provides limited coverage of the Oncotype DX DCIS assay for female patients diagnosed with DCIS who are planning breast-conserving surgery and are considering adjuvant radiation therapy. Coverage is restricted to that clinical scenario; the policy does not provide coverage details for other indications, nor does it list specific documentation or frequency limits.

"Oncotype DX® DCIS assay is covered for women diagnosed with ductal carcinoma in situ (DCIS) who are planning breast-conserving surgery and are considering adjuvant radiation therapy."

Sign up to see full coverage criteria, indications, and limitations.